Answers are grounded in this paper and cite their sources.
Obese asthma is a steroid-insensitive inflammatory phenotype with limited food-derived interventions. AMP2, purified from Atractylodes macrocephala, was identified as a glucose-rich branched glucan with a predominantly (→4)-Glcp-(1→-linked backbone and O-6 substitutions. To evaluate its effects and mechanisms, a high-fat diet (HFD)/house dust mite (HDM)-induced mouse model of obese asthma was established. Oral AMP2 ameliorated airway pathology and dyslipidemia, reduced macrophage infiltration and proinflammatory cytokine levels, and partially restored gut microbial richness and composition. Mechanistically, AMP2 suppressed pulmonary PAD4-associated neutrophil extracellular trap (NET) formation and the NLRP3/caspase-1/GSDMD signaling pathway in obese asthmatic mice. Consistently, AMP2 inhibited PAD4-associated NET formation in primary neutrophils, while GSK484 cotreatment provided no additional inhibition. Furthermore, NET-containing preparations derived from AMP2-treated neutrophils attenuated cell injury and pyroptotic activation in THP-1-derived macrophages. Collectively, these findings suggest that AMP2 alleviates obese asthma by suppressing PAD4-dependent NET formation and subsequent macrophage pyroptosis.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: